SCHEMBL13619996

SCHEMBL13619996

Cc1ccc(OC(=O)Nc2cc3c4c(c2)C(c2ccccc2)CCN4CCC3c2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.42
NPSR1 Q6W5P4 2/20 0.42
ALDH1A1 P00352 4/20 0.41
HTT P42858 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
BRD4 O60885 1/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
USP2 O75604 1/20 0.41
POLB P06746 1/20 0.40
EPHX2 P34913 1/20 0.40
RAB9A P51151 1/20 0.39
ACHE P22303 4/20 0.39
BCHE P06276 3/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2390941 0.92 ALDH1A1 (0.47) GAANPSR1ALDH1A1HTTSMN1; SMN2
SCHEMBL2391310 0.85 HTT (0.40) GAAALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL8989307 0.84 HPGD (0.38) GAAALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL2389189 0.84 LMNA (0.46) ALDH1A1MAPTKMT2AKDM4ERAB9A
SCHEMBL11995845 0.84 LMNA (0.46) ALDH1A1MAPTKMT2AKDM4ERAB9A
SCHEMBL13619982 0.83 GAA (0.37) GAANPSR1ALDH1A1HTTMAPT
SCHEMBL13625662 0.83 MAPT (0.43) GAAALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL8989317 0.81 CYP1A2 (0.42) ALDH1A1HTTSMN1; SMN2MAPTKDM4E
SCHEMBL14523185 0.81 SCN9A (0.43) GAAALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL1411660 0.80 RAB9A (0.48) ALDH1A1SMN1; SMN2MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009137342-A1 THERAPEUTICALLY USEFUL SUBSTITUTED 1, 7-DIPHENYL-L, 2, 3, 5, 6, 7-HEXAHYDROPYRIDO [ 3, 2, 1-I J ] QUINOLINE COMPOUNDS ALLERGAN, INC. (US) 2009-11-12 WO disclosed
US-20090281322-A1 THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS ALLERGAN, INC. (US) 2009-11-12 US disclosed
US-20090281322-A1 THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS ALLERGAN, INC. (US) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281322-A1 THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS GOT1, GOT2, NDUFA7 GAA 547/4885NPSR1 1998/4885ALDH1A1 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.